Tuesday, 15 Oct 2019

You are here

Allopurinol Shown to be Renal Protective

Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.

Historically, it has been claimed that allopurinol should be dose-adjusted in patients with renal insufficiency, implying that the drug may lend to renal impairment in susceptible individuals.

Researchers used a UK population for a prospective cohort study of newly diagnosed gout patients initiating allopurinol (≥300 mg/d) compared to those who did not initiate allopurinol. Thus, adults with newly diagnosed gout were propensity matched: 4760 initiators of allopurinol (≥300 mg/d) vs. the same number of noninitiators of allopurinol. Patients with chronic kidney disease stage 3 or higher or prior urate-lowering therapy were excluded.

Patients had a mean follow-up time of 4-5 years, mean age of 57 years, and mean body mass index 30.

Amongst these patients, chronic kidney disease stage 3 or higher was seen in 11.1% of allopurinol initiators and 13.1% of non-users.

Allopurinol (≥300 mg/d) was associated with a 13% lower risk of developing developing chronic kidney disease stage 3 or higher compared with nonusers (hazard ratio (HR) 0.87; 95% CI, 0.77-0.97).  Doses lower than 300 mg/d were not associated with protection against stage >3 CKD (HR, 1.00; 95% CI, 0.91-1.09).

Allopurinol dosed at 300 mg/d or higher was associated with a lower risk of renal function deterioration. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Anakinra Use in Hospitalized Gout Patients

While the efficacy and safety of interleukin 1 (IL-1) inhibitors (e.g., anakinra) in the acute management of gout and pseudogout has been repeatedly shown, the cost efficacy of such biologic therapy has rendered it impractical for most. A new retrospective study has shown that IL-1 inhibitors may be effective and appropriate for some medically complex, hospitalized patients with acute gout or calcium pyrophosphate crystal arthritis.

Higher Rates of Venous Thromboembolism in Gout

A Canadian administrative claims analysis has shown that gout-associated inflammation increases the risk of venous thromboembolism (VTE), deep vein thrombosis (DVT), and pulmonary embolism (PE) before and after the diagnosis of gout.

Modifiable Risk Factors for Hyperuricemia

Choi and colleagues have shown that four modifiable risk factors (BMI, the DASH diet, alcohol use, and diuretic use) could individually account for a notable proportion of observed hyperuricemia. 

Researchers examine modifiable risk factors for hyperuricemia and how this could be prevented through risk factor modification in the general population.

Opioids Overused in Acute Gout

Opioids were commonly given to patients as a treatment for acute gout attacks, despite the availability of other effective and appropriate therapies, a retrospective study found.

Allopurinol Fails to Curtail Hypertension

Editor's note: July 1 - 5, RheumNow is running the best of the EULAR 2019 meeting. A novel trial presented at EULAR 2019 last week assessed whether the use of urate-lowering therapy (ULT) would control hypertension in those at risk; however, results of this trial were largely negative.

Hypertension is one of the many comorbidities that plagues gout patients.